桑仙颗粒对中老年高血压病患者生活质量的影响及肾保护作用的研究
详细信息    本馆镜像全文|  推荐本文 |  |   获取CNKI官网全文
摘要
目的:本研究在中医理论的指导下,结合导师临床经验,提出肾中精气不足,血脉瘀阻是中老年高血压病的重要发病机制,确立补肾活血为本病的治疗大法,并据此拟定桑仙颗粒。旨在通过临床和实验两方面的研究,全面评价桑仙颗粒对高血压患者生活质量的影响,为中药疗效评价提供新的思路与方法;同时探讨其肾保护作用及机理,以期为中医药在此领域作出有益的探索。
    方法:临床研究选择80例肾虚血瘀型中老年高血压病患者,40例予桑仙颗粒治疗,40例予卡托普利作阳性对照组,分别对其进行系统临床观察及生活质量评价;动物实验选择自发性高血压大鼠(SHR),观察桑仙颗粒的降压及肾保护作用。
    结果:临床研究表明,桑仙颗粒可有效控制血压,降压总有效率为90.0%,改善症状总有效率为95%。同时能降低尿微量白蛋白、β_2—微球蛋白排泄,改善肾脏血流动力学,保护肾脏。在生活质量的评价中,试验组治疗前后在生理症状、躯体化症状、性功能失调、睡眠状况、活力、焦虑、工作状态、认知能力等方面均有明显改善。多项指标优于对照组。
    实验研究显示,桑仙颗粒即时、14天连续给药后,SHR血压都有明显下降。桑仙颗粒能明显增加正常大鼠及水负荷大鼠的排尿量,有一定的利尿作用;能增加大鼠肾组织的血流量;降低SHR肾组织中AngⅡ水平;抑制AT_1,受体的表达;下调转化生长因子基因表达。病理观察显示桑仙颗粒能减轻肾小球毛细血管基底膜增厚及系膜细胞增生,延缓肾小球硬化。
    结论:补肾活血是治疗中老年高血压病的重要治法。桑仙颗粒不仅有确切的降压疗效,而且能保护肾脏,改善患者的生活质量。为中医药治疗高血压病及全面评价中药疗效提供了新的思路与方法。
Objective: According to the TCM theory and the turtor's clinical experiences, a viewpoint was put forward that deficiency of kidney and stagnation of blood is the essential pathogenesis in senile hypertension. So strengthening kidney and promoting blood circulation are regarded as the therapeutic rules. The prescription of SangXian granule (SX) was developed in treating senile hypertension. This research try to evaluate SX's influence to the quality of life (QoL) of patients with senile hypertension and it's protective effect on kidney through clinical and experiental study, so as to make a beneficial attempt in this field in traditional Chinese medicine.
    Methods: 80 cases of senile hypertension belong to the sydrome of deficiency of kidney and stagnation of blood were observed in clinical trial. 40 cases were treated by SX and 40 cases by captopril. All cases have been maken systemic observations and assessments of QoL. Simultaneously, SX's protective effect on kidney was observed through SHR models in experimental study.
    Results: The clinical research showed that SX can evidently control blood-pressure and improve clinical symptoms. It's total rate of antihypertensive effect is 90.0%. It can also reduce ALB and P2-MG in urine and improve blood dynamics parameters, so as to protect kidney. In the assessments of QoL, SX can improve physical symptoms, body symptoms, sexual dysfunction, sleep dysfunction, energy, psycological state, work state and congnitive function in senile patients with hypertension. It's effect on QoL is better than control group. Experimental study showed that SX can control blood-pressure of SHR
    
    
    models, increase the quantum of urine and improve quantum of blood in kidney of normal rats, decrease the level of Ang II in kidney of SHR and inhibit the expression of AT1 and TGF-β1 mRNA in kidney. Pathological research showed that SX can reduce the damage and postpone sclerosis in kidney of SHR.
    Conclusion: Strengthening kidney and promoting blood circulation is a important therapeutic rule in treating senile hypertension. SX has good antihypertensive effect and protective effect on kidney, and can improve QoL as well. This research give a new idea and method in treating senile hypertension and evaluating the curative effect of antihypertensive medication in traditional Chinese medicine.
引文
[1] 中国高血压防治指南起草委员会.中国高血压防治指南.高血压杂志,2000;8(1):94-102.
    [2] Porish JG. Hypertension and chronic renal failure: the use of ACE inhibitors.AM J Kidney Dis, 1998,31:177-184.
    [3] Chalmers J al. WHO-ISH Hyertension Guidelines Committee. 1999 World Health Organization-Intenational Society of Hyertension Guidelines for the Management of Hypertension. J Hypertens, 1999. 17:151-185.
    [4] 沈自尹.中医虚证辨证参考标准.中西医结合杂志,1986;6(10):598.
    [5] 易法银.中医瘀血证诊疗大全,北京:中国中医药出版社,1996,第1版:8-10.
    [6] 李谢冰,林胜辉,林春燕.高血压病肾损害的探讨.放射免疫学杂志,2001;14(2):101-102.
    [7] 张蓉,卢涤,王志凯.高血压病的早期肾损害.医学综述,2000;6(5):206-207.
    [8] 李德新.中医基础理论.北京:中国中医药出版社,1999,第1版:72.
    [9] 高血压杂志编辑部.读者—作者—编者.高血压杂志,1998;6(1):65.
    [10] 中华人民共和国卫生部药政管理局.新药中药治疗老年病的临床研究指导原则.中国医药学报,1980;4(3):74.
    [11] Croog SH. Hypertensive black men and women. Arch Intern Med, 1990, 150 (8):1733-1741.
    [12] Testa MA, etal. Ashort form for clinical assessment of quality of life among hypertensive patients. Am, J Prey Med, 1989; 5(2): 82-89.
    [13] 杜勋明,吴艳,周有尚.高血压病人的生活质量测定.中国康复,1994,9(3),129-131.
    [14] 徐瑞,周聊生.原发性高血压早期肾损害超声多普勒肾血流测定的评价.临床心血管病杂志,2001;17(2):19-21.
    [15] 心血管病流行病学及人群防治汇报讨论会.常见心血管病流行病学研究及人群防治工作1979-1985年规划.中华心血管病杂志,1979;7(2):81.
    
    
    [16] 谢艳,顾振纶.氯沙坦和卡托普利联合应用对高血压大鼠肾脏的保护作用.中国药学杂志,2002;37(8):585-587.
    [17] 王冰注.黄帝内经素问.北京:商务印书馆,1955,第1版:4.
    [18] 赵伟康.中药延缓衰老的作用特点与研究途径.迈向21世纪的中西医结合.北京:中国医药科技出版社,1991,第1版:298.
    [19] 罗仁,钟洪.疾病人群的虚证特点.辽宁中医杂志,1996;23(4):154.
    [20] 张珍玉.灵枢经语释.济南:山东科学技术出版社,1983,第1版:316.
    [21] 南京中医学院.黄帝内经灵枢译释.上海:上海科学技术出版社,1986,第1版:218.
    [22] 张介宾.景岳全书.上海:上海科学技术出版社,1984,第1版:320.
    [23] 章真如.章真如医学十论.武汉:武汉出版社,1992,第1版:273.
    [24] 陈可冀.岳美中老中医治疗老年病的经验.北京:科学技术文献出版社,1978:27-28.
    [25] 林慧光.陈修圆医学全书.医学从众录.北京:中国中医药出版社,1999,第1版:679.
    [26] 陈梦雷.古今图书集成.医部全录.北京:人民卫生出版社,1983,第1版:1904.
    [27] 赵献可.医贯.北京:学苑出版社,1996,第1版,32.
    [28] 王清任.医林改错.北京:人民卫生出版社,1991,第1版:42.
    [29] 周学海.读医随笔.南京:江苏科学技术出版社,1981,第1版:159.
    [30] 钱来森.高血压、血液流变学和心血管结构功能改变之间的关系.国外医学。生理病理科学与临床分册,1990;10(2):130.
    [31] 龚兰生等.原发性和肾性高血压循环血栓素B2及6-前列腺素F2的改变.中华心血管病杂志,1986;14(1):31.
    [32] 欧亚龙等.高血压病血瘀关系的实验研究.四川中医,1991;(6):4.
    [33] 吴昆.黄帝内经素问吴注.北京:学苑出版社,2001,第1版:5。
    [34] 吴昆.黄帝内经素问吴注.北京:学苑出版社,2001,第1版:50.
    [35] 钱桐荪等.老年高血压病的肾损害.实用老年医学,1996;10(1):13-15.
    [36] Weng NK Mattson ME, Furberg CD etal. Assessment of quality of life in clinical trials of cardiovascular drugs. Am J Cardiol, 1984; 54: 908.
    
    
    [37] 李凌江,杨德森,王蓉等.高血压患者生活质量评估工具的研究.美国中华心身医学杂志(U.S.CPM),1997;1(4):203-206.
    [38] SM Hunt, etal. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health, 1980; 34:281-286.
    [39] Bergner M, etal. The Sickness Impact Profile: development and final revision of a health status measure. Med Care,1981; 19:787-805.
    [40] Lacourciere Y, etal. Analysis of well-being and 24 hour blood pressure recording in a comparative study between indapamide and captopril. Am J Med, 1988; 84:47-52.
    [41] Leonetti G, etal. Tolerability and well-being with indapamide in the treatment of mild-moderate hypentension. Am J Med, 1988; 84:59-64.
    [42] Croog SH, etal. Hypertensive black man and woman. Arch Inter Med, 1989; 150(17): 33-41.
    [43] Testa MA, etal. A short form for clinical assessment of quality of life among hypertensive patients. Am, J Prey Med, 1989; 5(2): 82-89.
    [44] 赵光胜主编.现代高血压病学.北京:人民军医出版社,1999:583-594.
    [45] Jachuck SJ, etal. The effects of hypotensive drugs on the quality of life. J Roy Coll Gen Pract, 1982; 32:103-105.
    [46] 秦方,阮蕾,朱轼,等.高血压患者生活质量及药物干预影响双盲研究(1026例报告).高血压杂志,2000;8(1):47.
    [47] Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lanat, 1988; 11: 539-544.
    [48] Chang SW, Fine R, Siegal D, etal. The impact of diuretic on reported sexual function. Br J clin pharmacol, 1984; 17: 524-529.
    [49] Leonetti G, Rappelli A, etal. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol, 1990; 65:67H-71H.
    [50] Curb JD, Borhani No, Blasokowski TP, et al. Long-term surveillance for
    
    adverse effects of antihypertensive drugs. JAWA, 1985; 253: 3263-3268.
    [51] Avon J, Everitt DE, Weiss S, et al. Increaseal antidepressant use in patients prescribed β-blockers. JAWA. 1986: 255: 357-360.
    [52] Thompson PD, Cullinane EM, Nugent AM, et al. The effect of atenolol and prazosin on maximal exercise performance in hypertensive joggers. Am J Med, 1989; 86: 104-109.
    [53] Fletcher AE, etal. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens,1989; 3:125-130.
    [54] palmer A, Fletcher A, Hamilton G, et al. A comparison of verapamil and nifedipine on quality of life. Brit J Clin pharm, 1990; 30: 365-370.
    [55] Israel-Biet D, Delaisements C, Chretein J, Enalapril-induced cough. Lancet, 1986; 2: 918.
    [56] Grimm RH, etal. Relationship of life measures to long-term lifestyle and drug treatment in the hypotension study. Arch Intern Med, 1997; 157:638-648.
    [57] 史宇广主编.头痛眩晕专辑.北京:中医古籍出版社,1992,第1版:165.
    [58] 刘力生主编.高血压.北京:人民卫生出版社,2001,第1版:901.
    [59] 严冬,蒋为民.降压益肾颗粒治疗高血压病早期肾损害35例疗效观察.中医药研究.1999;15(1):6-7.
    [60] 杨相维,李文浩.补肾活血汤为主治疗肾虚血瘀型慢性肾功能衰竭47例.浙江中医学院学报.1997;21(5):24-25
    [61] 张介宾.景岳全书.上海:上海科学技术出版社,1984,第1版:32.
    [62] 黄宫绣.本草求真.上海:上海科学技术出版社,1979,第1版:16.
    [63] 叶天士.本草再新.上海:群学社印行,民国八年,第1版:卷三:5.
    [64] 叶天士.本草再新.上海:群学社印行,民国八年,第1版:卷三:3.
    [65] 李时珍.本草纲目.北京:人民卫生出版社.1979,第1版:1451.
    [66] 陈嘉谟.本草蒙筌.北京:人民卫生出版社.1988,第1版:197.
    [67] 王筠默,等.神家本草经校证.吉林:吉林科学技术出版社,1987,第1版:220.
    [68] 陈士铎.本草新编.北京:中国中医药出版社,1996,第1版:206.
    
    
    [69] 倪朱漠.本草汇言.北京:中医古籍出版社,1997,第1版:卷九:6.
    [70] 转引江苏新医学院编中药大辞典.上海:上海科学技术社,1987,第1版:482.
    [71] 张介宾.景岳全书.上海:上海科学技术出版社,1959,第1版:911.
    [72] 汪昂.本草备要.上海:商务外出书馆,1955,第1版:1.
    [73] 转引江苏新医学院编中药大辞典.上海:上海科学技术出版社,1987,第1版:2025.
    [74] 王好古.汤液本草.北京:人民卫生出版社,1956,第1版:33.
    [75] 转引江苏新医学院编中药大辞典.上海:上海科学技术出版社,1987,第1版:2536.
    [76] 缪希雍.本草经疏.台北:文丰出版公司,1987:1024.
    [77] 周学海.读医随笔.南京:江苏科学技术出版社,1981,第1版.:48.
    [78] 转引江苏新医学院编中药大辞典.上海:上海科学技术出版社,1987,第1版:2022.
    [79] 转引江苏新医学院编中药大辞典.上海:上海科学技术出版社,1987,第1版:220.
    [80] 张介宾.景岳全书.上海:上海科学技术出版社,1984,第1版:31.
    [81] 张介宾.类经.上海:上海古籍出版社,1991,第1版:746.
    [82] 姜平.高血压的基本病机与中药降压作用.甘肃中医学院学报,1996;13(3):48.
    [83] 朱建贵.实用延寿中医学,北京:北京出版社,1990,第1版:124.
    [84] 刘江虹,沈连生.淫羊藿的研究进展.北京中医学院学报,1993;16(1):29.
    [85] 李宗友译.中药丹参中的紫草酸镁B对自发性高血压大鼠血压的抑制作用.国外医学.中医中药分册,1995:17(4):48-49.
    [86] 孙备译.丹参中的咖啡酸类似物对腺嘌呤所致肾性高血压大鼠的降压作用.国外医学.中医中药分册.1996.18(3):44-45.
    [87] 中华本草编委会.中华本草.上海科学技术出版社,1999,第1版,169-171.
    [88] 范维衡,徐远祥.杜仲叶和皮的药理作用研究.药学通报,1979:(4):404.
    [89] 苏印泉,马希汉,杨宗英.日本的杜仲研究开发综述.西北林学院学报,1996,11(2):94-100.
    [90] 吕兰熏.中药降压药的研究动态.陕西中医,1988:9(1):40-41.
    
    
    [91] 中华本草编委会.中华本草.上海:上海科学技术出版社,1999,第1版:2970.
    [92] 王浴生.中药药理与应用,北京:人民卫生出版社,1983,第1版:148.
    [93] 李仪奎,姜名瑛.中药药理学.北京:中国中医药出版社,1992,第1版:162.
    [94] 阴健,郭力弓,肖培根.中药现代研究与临床应用.北京:学苑出版社,1995,第1版:111.
    [95] 汤健.内皮素,北京:北京医科大学中国协和医科大学联合出版社,1994,第1版:16.
    [96] 刘力生主编.高血压.北京:人民卫生出版社,2001,第1版.234.
    [97] 傅良雄.心血管病学前沿研究,上海:上海科学技术文献出版社,1993,第1版:175.
    [98] 张维忠.高血压治疗研究的回顾与展望.中华心血管病杂志,2000;28(6):167.
    [99] 谌贻璞.高血压病肾损害.99中国高血压世纪行.
    [100] 刘力生主编.高血压.北京:人民卫生出版社,2001,第1版.903.
    [101] Hollenberg NK, Sandor T. Vasomotion of Renal Blood Flow in in Essential Hypertension. Oscillations in Xenon Transit [J].Hypertension, 1984, 6(4): 579-585.
    [102] 徐瑞,周聊生.原发性高血压早期肾损害超生多普勒肾血流测定的评价.临床心血管病杂志,2001,17(2),19-21.
    [103] Imuta N, Kinnoshita N, Etani H, et al. The reproducibility of color Doppler Duplex sonography in the measurement of renal arterial bloodvelocity [J].Ultrasound Med Biol,1997,23(6):813.
    [104] 梁春香,曲丽霞,张青,等.正常成人肾内血流动力学的彩色多普勒研究[J].中国超声,1995,11(2):103-106.
    [105] 王炼,姚绍球,杨斌,等.慢性肾病彩色多普勒血流图与肾皮质厚度及病理改变[J].中国超声,1996,12:43-44.
    [106] Parring HH, Saways B, Provenzano R, et al. Increased urinary albumin excretion rate in begeign essential hypertension. Lancel, 1974,1(3):1190.
    [107] Viberti GG, Jarowenko MV, Fiechner SM, et al. Effect of control blood
    
    glucose on urinary excretion of albumin and B-mi-crong-lubutin dependent diabetes. N Engi J Med, 1979, 22(2):638.
    [108] 刘力生主编.高血压.北京:人民卫生出版社.2001,第1版:768.
    [109] 刘为民,张名均,王宁.β2—微球蛋白、尿微量白蛋白测定对高血压病肾损害的评估.重庆医学,2002,31(2):151.
    [110] 朱鼎良主编.高血压临床新技术.北京:人民军医出版社,2002,第1版:34.
    [111] 陈孝文等主编.肾内分泌学.广东:广东科技出版社,1994,第1版:288.
    [112] 刘力生主编.高血压.北京:人民卫生出版社,2001,第1版:850.
    [113] Duhlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients [J]Am J Hypertens,1992;5:95.
    [114] Hollenberg NK. Evolution of the treatment hypertension :What really matters in the 1990s. Am J Med, 1992;93(supp12A):4-10.
    [115] 刘力生主编.高血压.北京:人民卫生出版社,2001,第1版:775.
    [116] 梁若梅.老年高血压病患者血液流学分析.中国高血压杂志,1994;2(1):58.
    [117] 苏江,钱自奋,梁晓春,等.活血降粘片治疗原发性高血压伴高粘滞综合征26例临床观察.中国中西医结合杂志,1995:15(11):681.
    [118] Khaw KT, Barrett CE. Blood pressure and endogenous testosterone in men:an inverse relationship. J Hypertens, 1998;6:329.
    [119] 秦方,阮蕾,朱轼,等.高血压患者生活质量及药物干预影响双盲研究(1026例报告).高血压杂志,2000;8(1):47.
    [120] Bohr DF, Dominiczak AF, Webb RC. Pathophysiology of vasculature in hyper-tension. Hypertension, 1991;18:Ⅲ115.
    [121] Banai S, Jaklitsch MT, Casscells W, et al Effects of acidic fibroblast growth factor on normal and ischemic myocardium, Ciyc Res, 1991;69:76.